Get regular updates to your inbox.
Soliris (eculizumab) safely and effectively treated chronic kidney disease in children with atypical hemolytic uremic syndrome (aHUS), a review study confirmed. Researchers suggested that more research is necessary, however, to establish its effectiveness, safety, and time of discontinuation in the long term. The review study, “The treatment…
Read more
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases have been selected to receive a Horizon Therapeutics‘ #RAREis Global Advocate Grant. Winners of this year’s inaugural awards are spread across nine countries and represent a total of 29 rare…
Soliris (eculizumab) safely and effectively treated a severe episode of atypical hemolytic uremic syndrome (aHUS) in an adolescent with another autoimmune disease called systemic lupus erythematosus (SLE), a case report described. The therapy’s use also was safely discontinued, without an aHUS relapse. The case study, “Successful Discontinuation…
In her final column for “Side-by-Side Effects,” aHUS caregiver Annie Dixon shares her greatest takeaway from her time as a weekly columnist.
Becoming educated and informed about aHUS is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnist’s words of wisdom to help you along on your aHUS journey.
There is no cure for aHUS yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
